Journal article
Acute Toxicity After CyberKnife-Delivered Hypofractionated Radiotherapy for Treatment of Prostate Cancer
American journal of clinical oncology, v 34(1), pp 6-10
01 Feb 2011
PMID: 20065849
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Objective: To evaluate acute toxicity outcomes of prostate cancer patients treated with CyberKnife-delivered hypofractionated radiotherapy.
Methods: This study was a retrospective chart review analysis of the first 50 patients treated with CyberKnife radiotherapy for prostate cancer. Most patients were affected with early to intermediate stage prostate cancer. Two patients had metastatic disease at presentation and were excluded. A total of 37 patients received irradiation at a dose of 35 to 37.5 Gy in 5 fractions of 7 to 7.5 Gy per fraction. Assuming an alpha/beta ratio of 1.5 Gy, this process delivered an equivalent dose of 85 to 96 Gy in 2 Gy fractions (EQD2). A subset of patients (n = 11) received standard linear accelerator-based pelvic radiation treatment either by intensity modulated radiation therapy or tomotherapy and received a boost via the CyberKnife at a dose of 17.6 to 25 Gy in 2 to 5 fractions (EQD2 = 46.6-72 Gy). The acute toxicities were recorded using the Common Terminology Criteria for Adverse Events, version 3.0, throughout treatment and at patients' follow-up visits.
Results: The median patient age at presentation was 66 years (range, 46-80). The mean pretreatment prostate specific antigen and Gleason scores were 9.16 ng/mL and 7, respectively. Grade 2 acute genitourinary toxicity was reported by 10% of patients (n = 5). Only 3 patients reported grade 3 acute genitourinary toxicity. No gastrointestinal grade 2 or grade 3 toxicities were reported.
Conclusions: CyberKnife-delivered hypofractionated radiotherapy for the treatment of prostate cancer has an acceptable acute toxicity profile.
Metrics
Details
- Title
- Acute Toxicity After CyberKnife-Delivered Hypofractionated Radiotherapy for Treatment of Prostate Cancer
- Creators
- Natasa C. Townsend - Drexel UniversityBradley J. Huth - Drexel Univ, Coll Med, Dept Radiat Oncol, Philadelphia, PA 19102 USAWilliam Ding - Drexel Univ, Coll Med, Dept Radiat Oncol, Philadelphia, PA 19102 USABruce Garber - Drexel Univ, Coll Med, Dept Radiat Oncol, Philadelphia, PA 19102 USAMichael Mooreville - Urol Care Ctr, Lansdowne, PA USAStephen Arrigo - Philadelphia CyberKnife Ctr, Havertown, PA USAJohn Lamond - Philadelphia CyberKnife Ctr, Havertown, PA USALuther W. Brady - Drexel University
- Publication Details
- American journal of clinical oncology, v 34(1), pp 6-10
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 5
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000286624100003
- Scopus ID
- 2-s2.0-79951642431
- Other Identifier
- 991019168722304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Oncology